Zhang Rongfeng

Prof. Zhang Rongfeng


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 September 2023 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
XZXiaobiao Zang
Xiaobiao Zang
ZZZhihan Zhao
Zhihan Zhao
KCKe Chen
Ke Chen
WSWeifeng Song
Weifeng Song
JMJi-fang Ma
Ji-fang Ma
ZRZhang Rongfeng
Zhang Rongfeng

23 June 2022 in Cardiology Research and Practice
Verified
Journal Article
Open access
PDF file
CMCheng-Ming Ma
Cheng-Ming Ma
YHYe-Jian He
Ye-Jian He
WLWenwen Li
Wenwen Li
HTHua-Min Tang
Hua-Min Tang
SDShi-Yu Dai
Shi-Yu Dai
ZRZhang Rongfeng
Zhang Rongfeng
The optimal catheter ablation (CA) strategy for patients with persistent atrial fibrillation (PeAF) and heart failure (HF) remains uncertain. Between 2016 and 2020, 118 consecutive patients with PeAF and HF who underwent the CA procedure in two centers were retrospectively evaluated and divided into the pulmonary vein isolation (PVI)-only and PVI + additional ablation groups. Transthoracic echocardiography (TTE) was performed at baseline, one month, and 12 months after the CA procedure. The HF symptoms and left ventricular ejection fraction (LVEF) improvements were analyzed. Fifty-six patients underwent PVI only, and 62 patients received PVI with additional ablation. Compared with the baseline, a significant improvement in the LVEF and left atrial diameter postablation was observed in all patients. No significant HF improvement was detected in the PVI + additional ablation group than in the PVI-only group (74.2% vs. 71.4%, ), but the procedure and ablation time were significantly longer (137.4 ± 7.5 vs. 123.1 ± 11.5 min, ). There was no significant difference in the change in TTE parameters and the number of rehospitalizations. For patients with PeAF and HF, CA appears to improve left ventricular function. Additional ablation does not improve outcomes and has a significantly longer procedure time. Trial registration number is as follows: ChiCTR2100053745 (Chinese Clinical Trial Registry; https://www.chictr.org.cn/index.aspx).

26 August 2022 in Medicine
Verified
Journal Article
Open access
YSYuanjun Sun
Yuanjun Sun
XYXiaohong Yu
Xiaohong Yu
XXXianjie Xiao
Xianjie Xiao
SDSHIYU DAI
SHIYU DAI
ZRZhang Rongfeng
Zhang Rongfeng
YXYunlong Xia
Yunlong Xia
Rationale: We reported a case with cardiomyopathy induced by frequent premature ventricular contractions (PVCs) and followed ventricular escape beats (VEBs). PVCs with VEBs in the compensatory pause which induced cardiomyopathy is rarely reported. Also, the case exhibited many characteristics of PVCs which were more likely to induce cardiomyopathy, like the location of origin, the longer coupling interval, and the QRS wave companied with the P wave. Patient concerns: A 53-year-old man with left ventricular (LV) dysfunction presented with palpation, chest distress, and dyspnea for 3 years. Holter revealed a high burden of ventricular rhythm of PVCs and another wide QRS patterns (96,562 total beats with 87,330 wide QRS beats in 24 hours). The LV ejection fraction decreased to 34% and the left ventricle, right and left atria all dilated. Diagnosis: He was diagnosed with PVC-induced cardiomyopathy. Interventions: The patient experienced intracardiac electrophysiological examination which revealed frequent PVCs followed by VEBs in the compensatory pause. Activation mapping of the PVCS and ablation were performed. Outcomes: PVCs and VEBs disappeared after ablation. The LV ejection fraction increased to 46% at 2 days after the procedure. The diameters of the right and left atria were also significantly reduced. Lessons: VEBs may occur during the compensatory pause of PVCs. PVCs with VEBs can lead to a high burden of ventricular rhythm and LV dysfunction. Ablation of the PVCs can also eliminate VEBs and improve the LV function.

19 June 2023 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Open access
ZRZhang Rongfeng
Zhang Rongfeng
HCHuimin Chu
Huimin Chu
SLShaowen Liu
Shaowen Liu
BYBing Yang
Bing Yang
BHBing Han
Bing Han
TIthe TRUEFORCE investigators.
the TRUEFORCE investigators.
Background: The use of contact force (CF) sensing catheters has provided a revolutionary improvement in catheter ablation (CA) of atrial fibrillation (AF) in the past decade. However, the success rate of CA for AF remains limited, and some complications still occur.Methods: The TRUEFORCE trial (Catheter Ablation of Atrial Fibrillation using FireMagic TrueForce Ablation Catheter) is a multicenter, prospective, single‐arm objective performance criteria study of AF patients who underwent their first CA procedure using FireMagic TrueForce ablation catheter.Results: A total of 120 patients (118 with paroxysmal AF) were included in this study, and 112 patients included in the per‐protocol analysis. Pulmonary vein isolation (PVI) was achieved in 100% of the patients, with procedure and fluoroscopy time of 146.63 ± 40.51 min and 12.89 ± 5.59 min, respectively. Freedom from recurrent atrial arrhythmia after ablation was present 81.25% (95% confidence interval [CI]: 72.78%–88.00%) of patients. No severe adverse events (death, stroke/transient ischemic attack [TIA], esophageal fistula, myocardial infarction, thromboembolism, or pulmonary vein stenosis) were detected during the follow‐up. Four (4/115, 3.33%) adverse events were documented, including one abdominal discomfort, one femoral artery hematoma, one coughing up blood, and one postoperative palpitation and insomnia.Conclusions: This study demonstrated the clinical feasibility of FireMagic force‐sensing ablation catheter in CA of AF, with a satisfactory short‐ and long‐term efficacy and safety.

30 May 2026 in npj Science of Food
Verified
Journal Article
Open access
PDF file
TLTao Li
Tao Li
BSBing Shao
Bing Shao
XLXiao Li
Xiao Li
ZWZiyi Wu
Ziyi Wu
DYDongxin Yi
Dongxin Yi
ZRZhang Rongfeng
Zhang Rongfeng
Hydroxytyrosol (HT), the most bioactive polyphenol in virgin olive oil, has been shown to have cardiometabolic benefits in obese rats, but the underlying mechanism has not been fully elucidated. The aim of this study was to explore the potential driving mechanism in the initiation node of obesity-induced myocardial fibrosis through in vivo and in vitro experiments, and the role of HT in obesity-induced myocardial fibrosis was investigated based on the above mechanisms. The results demonstrated that HT reduced cardiomyocyte oxidative stress and ultimately ameliorated myocardial injury and fibrosis in obese mice by inhibiting NLRP3 inflammasome-dependent pyroptosis, which in turn downregulated the deubiquitinating enzyme cylindromatosis (CYLD), thereby reducing NADPH oxidase (NOX)4 deubiquitination and promoting its degradation. The alternative text for this image may have been generated using AI.